Severe COVID-19 Outcomes in Five Latin American Countries in the Postvaccination Era
Author:
Silva Julian Guilherme1ORCID, Spinardi Júlia23, Diaz-Puentes Melissa4, Buitrago Diana4ORCID, García Ida Caterina5, Kyaw Moe H.6ORCID
Affiliation:
1. Evidence Generation Medical Affairs, Pfizer Inc., São Paulo 04717-904, Brazil 2. Vaccines Medical Affairs, Pfizer Inc., São Paulo 04717-904, Brazil 3. Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo 01224-001, Brazil 4. Real World Insights (RWI), IQVIA, Bogotá 110110, Colombia 5. Real World Insights (RWI), IQVIA, Ciudad de México C.P. 03810, Mexico 6. Vaccines Clinical Epidemiologist Emerging Markets, Pfizer Inc., Collegeville, PA 19426-3982, USA
Abstract
We conducted a multicountry retrospective study using data from COVID-19 national surveillance databases to analyze clinical profiles, hospitalization rates, intensive care unit (ICU) admissions, utilization of ventilatory support, and mortality rates in five Latin American countries in the context of COVID-19 vaccination implementation. We analyzed the sociodemographic characteristics, comorbidities, clinical outcomes, and vaccination status of laboratory-confirmed COVID-19 cases from January 2021 to December 2022. We calculated the yearly and quarterly hospitalization rates per 1000 confirmed COVID-19 cases and ICU admissions, use of mechanical ventilators, and mortality rates per 1000 hospitalized cases, with their corresponding 95% confidence interval (CI) of 38,852,831 confirmed COVID-19 cases. Rates of hospitalization, ICU admission, ventilatory support, and death were higher among males than among females (38.2 vs. 32.4, 148.4 vs. 117.7, 282.9 vs. 236.2, and 346.9 vs. 320.1 per 1000, respectively); higher in 2021 than in 2022 (50.7 vs. 19.9, 207.8 vs. 58.2, 441.5 vs. 114.9, and 352.5 vs. 285.2 per 1000, respectively); and in the >50 age group (range: 5.7–18.6, 20.1–71.5, 12.2–67.9, and 353.1–577.4, per 1000) than the <50 age group (range: 2.2–9.3, 5.4–33.2, 41.4–135.8, and 22–243.5 per 1000). Hypertension and diabetes mellitus were the most common comorbidities in Mexico and Colombia. Prevention and treatment strategies for these case profiles could bring benefits from a public health perspective.
Reference32 articles.
1. World Health Organization (2023, November 15). WHO Coronavirus (COVID-19) Dashboard. Available online: https://data.who.int/dashboards/covid19/cases?n=c. 2. PAHO (2024, January 05). Cumulative Confirmed and Probable COVID-19 Cases Reported by Countries and Territories in the Region of the Americas. Available online: https://ais.paho.org/phip/viz/COVID19Table.asp. 3. COVID-19 in Latin America: A Snapshot in Time and the Road Ahead;LaRotta;Infect. Dis. Ther.,2023 4. Kim, Y.C., and Arturo, R.-S. (2022). Viral-Vectored Vaccines against SARS-CoV-2. Biomedical Innovations to Combat COVID-19, Academic Press. 5. Graña, C., Ghosn, L., Evrenoglou, T., Jarde, A., Minozzi, S., Bergman, H., Buckley, B.S., Probyn, K., Villanueva, G., and Henschke, N. Efficacy and Safety of COVID-19 Vaccines. Cochrane Database Syst. Rev., 2022.
|
|